Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis/HGS’ Albuferon ACHIEVEs Non-inferiority To Pegasys For Hepatitis C

This article was originally published in The Pink Sheet Daily

Executive Summary

Question now is whether the long-acting version of interferon will be able to make a “me-better” case based on dosing and quality of life benefits.

You may also be interested in...



Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince

Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.

Albuferon ACHIEVE-1 Study Shows Non-Inferiority To Pegasys, But That Fails To Convince

Final Phase III study of Human Genome Sciences/Novartis' hepatitis C drug meets primary endpoint, but Pegasys does better numerically, leading to poor reception on the Street.

Albuferon Dosing Advantage: Less Is More For HCV Patients, Physicians Say

The dosing advantage for Novartis/Human Genome Sciences' follow-on interferon product Albuferon is enough to establish the hepatitis C therapy over Roche's go-to treatment Pegasys, according to a physician panel at the BIO CEO conference - quelling concerns that less frequent dosing might not be enough to get practitioners to switch to the new product

Related Content

Topics

UsernamePublicRestriction

Register

ID005817

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel